METHOD OF SUBLINGUAL ALLERGEN-SPECIFIC IMMUNOTHERAPY (SASI) OF POLLINOSIS WITH HYPOSENSITIZATION AGENT Russian patent published in 2020 - IPC A61K39/35 A61P37/08 

FIELD: medicine.

SUBSTANCE: invention refers to immunology and allergology, and concerns treating pollinosis. Method of sublingual allergen-specific immunotherapy (SASI) of pollinosis with hyposensitizer is characterized by that before the beginning of treatment control of tablets for identification of proteins and ascorbic acid and quantitative determination of allergen-specific IgE in patient's blood serum, specific to corresponding IAA antibodies, followed by administering said therapeutic composition for three courses: initial course at dilutions: 10^-8, 10^-7, 10^-6, 10^-5, 10^-4 1 tablet a day: blister No. 1 - 0.0001 PNU; blister No. 2 - 0.001 PNU; blister No. 3 - 0.01 PNU; blister No. 4 - 0.1 PNU; blister No. 5 - 1 PNU for 6 days; main course at dilutions of 10^-3, 10^-2: blister number 6 – 10 PNU and blister number 7 – 100 PNU (both 1 tablet day for 6 days) and blister number 8 – 1000 PNU with dilution of 10^-1 1 tablet every other day for 11 days; maintaining the course of dilution 10^-1 blister number 9 – 1000 PNU 1 tablet every 1 or 2 days for 11–16 days, wherein safety of sublingual allergen-specific immunotherapy is assessed by frequency and severity of negative manifestations of IAA: itching in the oral cavity at the place of allergen application, puffiness of lips, swelling of tongue, sore throat, numbness of tongue, and also: rhinoconjunctivitis, nausea, abdominal pain, weakness, fatigue, itching in the auricles, wherein the immunotherapy is started with a minimum dose of allergen-active ingredient 0.0001 and the dose is gradually increased, and the dose of the administered IAA over the whole course of administration is increased by 10,000,000–100,000,000 times.

EFFECT: invention provides higher clinical-immunological effect and reduced risk of anaphylactic shock.

6 cl, 3 ex